Abstract
The inhibition of β-secretase has become a very promising approach to control the onset and progression of Alzheimers disease due to its involvement in the generation of amyloid plaques. The main goal of the many drug discovery projects targeting this enzyme is the identification of highly specific, non-peptidic compounds with low molecular weight, characteristics that are desirable for drug leads with low toxicity that have to transverse the blood brain barrier. We describe the main approaches used in the discovery of novel inhibitors, including substrate specificity, target structure based design, and high throughput screening (HTS), both in vitro and in silico. We place special emphasis in the receptor based design and in silico HTS, two strategies that make wide use of computer assisted tools. To exemplify the usefulness and versatility of computer tools in this endeavor we use the computer generated ‘enzymes binding site cast’ to rationalize qualitatively some salient structural features of known β-secretase second generation inhibitors, and for guiding the review of many of the ligands whose complexes with the enzyme have been studied by X-ray crystallography. We discuss the use made by other authors of molecular modelling for the understanding of the very special characteristics of ligand binding to β-secretase and for the design of new inhibitors. Finally, we review the quest for non-peptidic inhibitors that has led to the use of HTS in vitro and in silico. The screening of extensive libraries resulted in a few low affinity compounds that do not fit into the key S1/S1 pockets, indicating that this is not an easy target to block.
Keywords: BACE 1, OM99-1, X-Ray Crystrallography, Apo-Enzyme, hydroxyethylene
Current Topics in Medicinal Chemistry
Title: The Search for Drug Leads Targeted to the β -Secretase: An Example of the Roles of Computer Assisted Approaches in Drug Discovery
Volume: 7 Issue: 10
Author(s): M. Carmen Villaverde, Lucia Gonzalez-Louro and Fredy Sussman
Affiliation:
Keywords: BACE 1, OM99-1, X-Ray Crystrallography, Apo-Enzyme, hydroxyethylene
Abstract: The inhibition of β-secretase has become a very promising approach to control the onset and progression of Alzheimers disease due to its involvement in the generation of amyloid plaques. The main goal of the many drug discovery projects targeting this enzyme is the identification of highly specific, non-peptidic compounds with low molecular weight, characteristics that are desirable for drug leads with low toxicity that have to transverse the blood brain barrier. We describe the main approaches used in the discovery of novel inhibitors, including substrate specificity, target structure based design, and high throughput screening (HTS), both in vitro and in silico. We place special emphasis in the receptor based design and in silico HTS, two strategies that make wide use of computer assisted tools. To exemplify the usefulness and versatility of computer tools in this endeavor we use the computer generated ‘enzymes binding site cast’ to rationalize qualitatively some salient structural features of known β-secretase second generation inhibitors, and for guiding the review of many of the ligands whose complexes with the enzyme have been studied by X-ray crystallography. We discuss the use made by other authors of molecular modelling for the understanding of the very special characteristics of ligand binding to β-secretase and for the design of new inhibitors. Finally, we review the quest for non-peptidic inhibitors that has led to the use of HTS in vitro and in silico. The screening of extensive libraries resulted in a few low affinity compounds that do not fit into the key S1/S1 pockets, indicating that this is not an easy target to block.
Export Options
About this article
Cite this article as:
Carmen Villaverde M., Gonzalez-Louro Lucia and Sussman Fredy, The Search for Drug Leads Targeted to the β -Secretase: An Example of the Roles of Computer Assisted Approaches in Drug Discovery, Current Topics in Medicinal Chemistry 2007; 7 (10) . https://dx.doi.org/10.2174/156802607780906708
DOI https://dx.doi.org/10.2174/156802607780906708 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Unfolding Cardiac Amyloidosis –From Pathophysiology to Cure
Current Medicinal Chemistry Nucleoside Transporter Proteins
Current Vascular Pharmacology The Emerging Role of Melatonin Agonists in the Treatment of Major Depression: Focus on Agomelatine
CNS & Neurological Disorders - Drug Targets Metabolic Correction in the Management of Diabetic Peripheral Neuropathy: Improving Clinical Results Beyond Symptom Control
Current Clinical Pharmacology L-Carnosine Modulates Respiratory Burst and Reactive Oxygen Species Production in Neutrophil Biochemistry and Function: May Oral Dosage Form of Non-Hydrolized Dipeptide L-Carnosine Complement Anti-Infective Anti-Influenza Flu Treatment, Prevention and Self-Care as an Alternative to the Conventional Vaccination?
Current Clinical Pharmacology Parallel Roles for Dopamine in Pathological Gambling and Psychostimulant Addiction
Current Drug Abuse Reviews Drug-Drug Interactions: Antiretroviral Drugs and Recreational Drugs
Recent Patents on CNS Drug Discovery (Discontinued) Meet Our Editorial Board Member
Current Alzheimer Research Effects of pH and Arginine on the Solubility and Stability of a Therapeutic Protein (Fibroblast Growth Factor 20): Relationship between Solubility and Stability
Current Pharmaceutical Biotechnology A Study on Building a Monte Carlo Model of G4 CyberKnife Based on the Third-party Softwares
Neuroscience and Biomedical Engineering (Discontinued) New Potential Pharmaceutical Applications of Hypericum Species
Mini-Reviews in Medicinal Chemistry Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Amyloid-Degrading Enzymes as Therapeutic Targets in Alzheimers Disease
Current Alzheimer Research Transgenic Mouse Models with Tau Pathology to Test Therapeutic Agents for Alzheimers Disease
Mini-Reviews in Medicinal Chemistry Vaccine Therapy Update for Pregnant, Immunocompromised, and Chronic Diseases Patients
Recent Patents on Inflammation & Allergy Drug Discovery Molecular Docking Studies of Novel Arylidene-2, 4-Thiazolidinediones as Potential Aldose Reductase Inhibitors
Letters in Drug Design & Discovery Inflammation, High Density Lipoprotein and Endothelium
Current Medicinal Chemistry Bivalent Ligands for G Protein-Coupled Receptors
Current Pharmaceutical Design Role of Methylene Blue in Trauma Neuroprotection and Neuropsychiatric Diseases
CNS & Neurological Disorders - Drug Targets Serotonin Transporter Gene Variants and Behavior: A Comprehensive Review
Current Drug Targets